Alphamab Oncology Reports Phase III Clinical Success for Anbenitamab (KN026) in HER2+ Advanced Breast Cancer – Key Data and Shareholder Insights
Key Highlights
- Phase III clinical study of Anbenitamab (KN026) as first-line treatment for HER2+ advanced breast cancer met primary endpoint of progression-free survival (PFS)
- Study demonstrated statistically significant and clinically meaningful benefits versus current standard-of-care (THP regimen)
- Potential to challenge current global and China standard-of-care for HER2+ advanced breast cancer
- Data to be presented at upcoming international academic conference
- Multiple ongoing registrational studies and upcoming NDA submission for HER2+ breast cancer
- Orphan Drug Designation from US FDA and Breakthrough Therapy Designation from China NMPA for gastric cancer indications
Detailed Report for Investors
Alphamab Oncology (Stock Code: 9966) has announced a potentially game-changing advancement in its oncology pipeline. The company’s Phase III clinical study (KN026-003) of Anbenitamab (KN026)—a proprietary anti-HER2 bispecific antibody—has met its pre-specified primary endpoint for progression-free survival (PFS) when used as a first-line treatment in HER2+ advanced breast cancer.
About the Study
- The trial was a randomized, controlled, open-label, multi-center Phase III study enrolling approximately 880 patients with HER2+ advanced breast cancer, randomized 1:1.
- It compared the efficacy and safety of Anbenitamab plus albumin-bound docetaxel (HB1801) against the current standard-of-care THP regimen (trastuzumab + pertuzumab + docetaxel).
- The study’s primary endpoint was progression-free survival (PFS) as assessed by a blinded independent committee.
- According to the Independent Data Monitoring Committee, the Anbenitamab arm significantly prolonged PFS and reduced the risk of disease progression or death compared to the THP regimen. There was also a positive trend toward improved overall survival.
- Further details will be presented at an upcoming international conference, which could further enhance global visibility and interest.
Market Implications and Unmet Needs
- Breast cancer remains a leading malignancy among women in China, with HER2+ subtype accounting for 20-30% of cases.
- 20% of Chinese breast cancer patients are diagnosed at an advanced stage; about 10% of early-stage HER2+ patients relapse within three years post-surgery.
- While the THP regimen is the global first-line standard, about 50% of patients still progress within 2 years, highlighting significant unmet needs that Anbenitamab aims to address.
About Anbenitamab (KN026)
- Anbenitamab is an Fc-based bispecific antibody developed using Alphamab’s proprietary CRIB platform, capable of binding two unique HER2 epitopes, blocking the HER2 pathway, inducing receptor clustering, and enhancing immune-mediated cancer cell killing.
- Already approved in China (May 2026) for combination with chemotherapy in HER2+ gastric/gastroesophageal cancers post-trastuzumab, under the NMPA’s priority review channel.
- Holds Orphan Drug Designation from the US FDA for HER2+ or HER2-low gastric cancer, and Breakthrough Therapy status from China’s NMPA for advanced gastric cancer.
- Multiple registrational trials ongoing for breast and gastric cancer, including adjuvant and first-line settings, with a New Drug Application (NDA) for neoadjuvant HER2+ breast cancer treatment planned soon.
- Exclusive development and commercialization rights for breast and gastric cancers in mainland China (excluding HK, Macau, Taiwan) licensed to JMT-Bio, a CSPC Group subsidiary.
About Docetaxel (Albumin-Bound) for Injection (HB1801)
- Developed by CSPC Group, this novel formulation offers improved safety (no steroid premedication required, absence of Tween-80/ethanol), rapid high-concentration administration, and potential for higher dosing and enhanced efficacy.
- HB1801 is in pivotal phase III trials for both breast and gastric cancer.
Shareholder and Price-Sensitive Insights
- The successful Phase III readout demonstrates both statistical and clinical superiority over the current first-line standard, making Anbenitamab a potential new standard-of-care for HER2+ advanced breast cancer.
- The imminent NDA submission for neoadjuvant HER2+ breast cancer and ongoing registrational studies could open up large market opportunities and drive future revenues.
- The company’s innovative pipeline, with two NMPA-approved products and multiple late-stage candidates, positions it as a leading oncology biopharma in China. These advancements are likely to attract significant investor interest and could positively impact share price.
- However, the company notes that there is no guarantee KN026 will be approved for indications beyond its current gastric cancer label, and investors should exercise caution.
Conclusion
The positive Phase III results for Anbenitamab in HER2+ advanced breast cancer represent a significant milestone for Alphamab Oncology, with the potential to reshape the treatment landscape and drive substantial shareholder value. The company’s robust pipeline and regulatory designations further strengthen its strategic position. Investors should closely monitor upcoming conference data presentations and regulatory milestones, which could be major share price catalysts.
Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Forward-looking statements involve risks and uncertainties. Investors should exercise caution and consider their own circumstances before acting on any information herein.
康寧傑瑞生物（9966）Anbenitamab（KN026）治療HER2+晚期乳腺癌三期臨床試驗達標 – 詳細報告及股東須知
重點摘要
- Anbenitamab（KN026）作為HER2+晚期乳腺癌一線治療的三期臨床試驗，達到主要終點（無進展生存期PFS）
- 試驗顯示對比現有標準治療（THP方案），在統計及臨床上均有顯著優勢
- 有潛力挑戰中國及全球現時HER2+乳癌一線治療標準
- 詳細數據將於即將舉行的國際學術會議公佈
- 多項註冊性研究進行中，並計劃盡快提交NDA申請（新藥申請）
- 已獲美國FDA孤兒藥資格及中國NMPA突破性治療認定（胃癌適應症）
投資者詳細報告
康寧傑瑞生物（9966）宣布其重磅管線Anbenitamab（KN026）三期臨床試驗取得突破性進展。該藥物用於HER2+晚期乳腺癌一線治療的隨機、多中心對照臨床（KN026-003）已達到預設主要終點——無進展生存期（PFS）。
試驗詳情
- 該三期臨床為隨機、對照、開放多中心設計，入組約880名HER2+晚期乳腺癌患者，1:1分組。
- 比較Anbenitamab聯合白蛋白結合多西他賽（HB1801）與現時一線標準THP方案（曲妥珠單抗+帕妥珠單抗+多西他賽）的療效與安全性。
- 主要終點為無進展生存期（PFS），由獨立評審委員會盲法評估。
- 根據獨立數據監查委員會評估，Anbenitamab組顯著延長PFS、降低疾病進展或死亡風險，整體生存期亦有改善趨勢。
- 詳細臨床數據將於國際學術會議發佈，有望提升市場及專業關注度。
市場影響及未被滿足需求
- 乳腺癌為中國女性發病率最高的惡性腫瘤之一，HER2+亞型佔比達20-30%。
- 中國約20%乳腺癌患者初診已屬晚期，HER2+早期患者約10%三年內復發。
- 雖然THP方案為全球一線標準，但仍有50%患者兩年內疾病進展，臨床需求巨大，Anbenitamab有望彌補部分缺口。
Anbenitamab（KN026）簡介
- 公司自主CRIB平台開發的Fc異源雙特異性抗體，同時結合HER2兩個不同表位，實現信號阻斷及受體下調，增強免疫攻擊腫瘤能力。
- 2026年5月已於中國獲批上市（優先審評），用於HER2+胃/胃食管癌經曲妥珠單抗治療後的患者。
- 獲美國FDA孤兒藥資格及中國NMPA突破性療法認定（胃癌適應症）。
- 多項乳腺癌及胃癌註冊性臨床進行中，包括一線、輔助及新輔助治療，近期將提交新藥申請。
- 2021年授予石藥集團子公司JMT-Bio於中國大陸（不含港澳台）獨家開發及商業化權利。
白蛋白結合多西他賽（HB1801）簡介
- 石藥集團自主納米製劑平台開發，無需類固醇預處理，無Tween-80及乙醇，安全性更高，可高劑量快速給藥，有助提升臨床效果。
- HB1801現正於乳癌及胃癌開展關鍵三期試驗。
股東及價格敏感資訊
- 三期臨床成功顯示Anbenitamab對比現有標準具明顯優勢，有望成為HER2+晚期乳腺癌新一線標準。
- 新輔助適應症即將申報NDA及多項註冊性臨床推進，有望帶來龐大市場及收入增長。
- 公司創新管線豐富，兩款產品已獲批上市，多項候選藥進入三期或關鍵臨床，行業競爭力突出，預期將吸引投資者關注，有利股價表現。
- 但公司提示，KN026能否於其他適應症（除已批准胃癌）獲批上市尚存不確定性，投資者需審慎。
結論
Anbenitamab於HER2+晚期乳腺癌三期試驗取得的積極數據，對公司管線及行業地位具有重大里程碑意義，未來國際會議數據公佈及潛在新適應症申請均為重要催化劑，值得投資者密切關注。
免責聲明：本新聞稿僅供參考，並不構成投資建議。前瞻性陳述存在不確定性，投資者應根據自身情況審慎決定。
